AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Shun LuXiaorong DongHong JianJianhua ChenGongyan ChenYuping SunYinghua JiZiping WangJianhua ShiJunguo LuShaoshui ChenDongqing LvGuojun ZhangChunling LiuJuan LiXinmin YuZhong LinZhuang YuZhehai WangJiuwei CuiXingxiang XuJian FangJifeng FengZhi XuRui MaJie HuNong YangXiangdong ZhouXiaohong WuChengping HuZhihong ZhangYou LuYanping HuLiyan JiangQiMing WangRenhua GuoJianying ZhouBaolan LiChunhong HuWancheng TongHelong ZhangLin MaYuan ChenZhijun JieYu YaoLongzhen ZhangWeng JieWeidong LiJianping XiongXianwei YeJianchun DuanHaihua YangMeili SunChangan SunHongying WeiChuan LiSiraj M AliVincent A MillerQiong WuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
-mutant NSCLC in the first-line setting.